TriangleFOR PATIENTS · SOURCE READING
Treatment of Myelodysplastic/ Myeloproliferative Neoplasm, Unclassifiable
Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: March 6, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
Because myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC) is a rare disease, little is known about its treatment. Treatment may include:
Source links and citations
supportive care treatments to manage problems caused by the disease such as infection, bleeding, and anemia
Source links and citations
targeted therapy (imatinib mesylate)
Source links and citations
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice